Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Faivre

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Bulletin Du Cancer|October 15, 1998
[Molecular mechanism in the regulation of apoptosis]S Faivre
Current Oncology (Toronto, Ont.)|December 10, 2014
Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumoursE Raymond, S Faivre
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2006
Management of neuromuscular dose limiting toxicity at the early stage of drug developmentS Faivre, E Raymond
Oral Oncology|September 1, 2016
Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et alP Szturz, S Faivre
La Revue De Medecine Interne|March 21, 2009
[Targeted therapies and their indications in solid neoplasias]C Dreyer, E Raymond, S Faivre
La Revue De Medecine Interne|June 20, 2003
[Epidermal growth factor inhibitors]C Delbaldo, S Faivre, E Raymond
Drug Safety|December 20, 1999
A risk-benefit assessment of amifostine in cytoprotectionM Mabro, S Faivre, E Raymond
Bulletin Du Cancer|May 27, 2009
[Targeted therapies in hepatocellular carcinomas: recent results and future development]H Marijon, S Faivre, E Raymond
Digestive Diseases (Basel, Switzerland)|December 5, 2012
Surgical results after downstaging of initially marginal or non-resectable liver metastasesF Cauchy, S Faivre, J Belghiti
Cancer Treatment Reviews|November 7, 2007
New developments in multitargeted therapy for patients with solid tumoursC Le Tourneau, S Faivre, E Raymond
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Bulletin Du Cancer|October 15, 1998
[Molecular mechanism in the regulation of apoptosis]S Faivre
Current Oncology (Toronto, Ont.)|December 10, 2014
Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumoursE Raymond, S Faivre
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2006
Management of neuromuscular dose limiting toxicity at the early stage of drug developmentS Faivre, E Raymond
Oral Oncology|September 1, 2016
Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et alP Szturz, S Faivre
La Revue De Medecine Interne|March 21, 2009
[Targeted therapies and their indications in solid neoplasias]C Dreyer, E Raymond, S Faivre
La Revue De Medecine Interne|June 20, 2003
[Epidermal growth factor inhibitors]C Delbaldo, S Faivre, E Raymond
Drug Safety|December 20, 1999
A risk-benefit assessment of amifostine in cytoprotectionM Mabro, S Faivre, E Raymond
Bulletin Du Cancer|May 27, 2009
[Targeted therapies in hepatocellular carcinomas: recent results and future development]H Marijon, S Faivre, E Raymond
Digestive Diseases (Basel, Switzerland)|December 5, 2012
Surgical results after downstaging of initially marginal or non-resectable liver metastasesF Cauchy, S Faivre, J Belghiti
Cancer Treatment Reviews|November 7, 2007
New developments in multitargeted therapy for patients with solid tumoursC Le Tourneau, S Faivre, E Raymond
Pageof 7